BELITE BIO, INC
BLTE evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $6.97B
What it means
What to watch
Prepared research question
What matters most for BLTE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BLTE
Belite Bio, Inc (BLTE) is a clinical-stage drug development company focused on advancing novel therapeutics for degenerative retinal diseases, with its lead candidate tinlarebant under FDA Priority Review for Stargardt disease type 1.
Key risk: Regulatory approval uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$6.97B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 3 clinical trials for BELITE BIO, INC.
Belite Bio, Inc (BLTE) is a clinical-stage drug development company focused on advancing novel therapeutics for degenerative retinal diseases, with its lead candidate tinlarebant under FDA Priority Review for Stargardt disease type 1.
- FDA accepted the NDA for tinlarebant with Priority Review for Stargardt disease type 1; PDUFA target action date is February 12, 2027 [news · published 2026-08-11]
- Tinlarebant met the primary endpoint in the Phase 3 DRAGON trial with a 36% reduction in lesion growth (p-value=0.0033) [news · published 2026-01-27]
- Cash & equivalents of $352.9M and shareholders' equity of $770.5M as of 2025-12-31 [sec]
- Enrollment completed in the DRAGON II clinical trial for Stargardt disease with 60 adolescent subjects across Japan, the US, and the UK [news · published 2026-01-27]
- Japanese NDA for tinlarebant in Stargardt disease type 1 submitted in September 2026 [news · published 2026-09-08]
What works
- Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal Phase 3 DRAGON trial [news · published 2026-01-27]
- FDA granted Priority Review for the NDA, indicating the agency's recognition of the potential for a significant improvement over available therapies [news · published 2026-08-11]
- The company has a strong cash position of $352.9M as of 2025-12-31, providing substantial runway for operations and potential commercialization [sec]
What to weigh
- The company is still pre-revenue and clinical-stage, with no approved products to date [news · published 2026-10-01]
- Widening losses were reported in Q2 2026, though specific figures are not detailed in the provided chunks [news · published 2026-08-14]
- The geographic atrophy (GA) trial interim analysis has been delayed, which may affect pipeline timelines [news · published 2026-08-14]
From the filings
Quoted directly from source documents.
FDA accepted NDA with Priority Review for tinlarebant
“U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027”
News · August 13, 2026
Tinlarebant met primary endpoint in Phase 3 DRAGON trial
“Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p-value=0.0033)”
News · January 27, 2026
Catalyst timeline
- 2022-03-28 · Phase 3 DRAGON trial start (Stargardt disease) — Initiated the pivotal Phase 3 trial for tinlarebant in adolescent Stargardt disease subjects.
- 2023-07-27 · Phase 3 PHOENIX trial start (geographic atrophy) — Started the Phase 3 study for tinlarebant in geographic atrophy; interim analysis has been delayed.
- 2024-07-31 · Phase 1b/2-3 start (Japanese Stargardt disease) — Began studies in Japanese subjects to support regional regulatory submission.
Risks & what to watch (3)›
Key risks
- Regulatory approval uncertainty — Tinlarebant's NDA is under FDA review; approval is not guaranteed and the PDUFA date is Feb 12, 2027 [news · published 2026-08-11]
- Pre-revenue stage — Belite Bio has no approved products and relies on cash reserves to fund operations and potential launch [news · published 2026-10-01]
- Delayed GA trial interim analysis — The interim analysis for the geographic atrophy (PHOENIX) trial has been delayed, potentially affecting pipeline progress [news · published 2026-08-14]
What to watch
- PDUFA target action date for tinlarebant NDA on February 12, 2027 [news · published 2026-08-11]
- Outcome of the Japanese NDA submission for tinlarebant [news · published 2026-09-08]
- Data presentations at upcoming medical conferences (Euretina, AAO, Innovate Retina) in late 2026 [news · published 2026-10-01]
- Progress and interim analysis of the Phase 3 PHOENIX study for geographic atrophy [catalyst]
Sources: Catalysts · News · Generated October 3, 2026 · How we verify sources →
Run BELITE BIO, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BELITE BIO, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.01
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 115 sells (180d)
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 6.0%
- Days to cover
- 8.8
- Shares short
- 1,233,097
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BLTE short interestFrequently asked questions
What is the AI investment thesis for BELITE BIO, INC?
Belite Bio, Inc (BLTE) is a clinical-stage drug development company focused on advancing novel therapeutics for degenerative retinal diseases, with its lead candidate tinlarebant under FDA Priority Review for Stargardt disease type 1.
Who is the CEO of BELITE BIO, INC?
Dr. Yu-Hsin Lin M.B.A., Ph.D. is the chief executive officer of BELITE BIO, INC (BLTE).
Where is BELITE BIO, INC headquartered?
BELITE BIO, INC (BLTE) is headquartered in San Diego, CA, United States.
What therapeutic areas does BELITE BIO, INC focus on?
BELITE BIO, INC develops therapies across Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.